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We recently reported that SMAP1, a GTPase-activating protein (GAP) for Arf6, directly interacts with clathrin and
regulates the clathrin-dependent endocytosis of transferrin receptors from the plasma membrane. Here, we identified a
SMAP1 homologue that we named SMAP2. Like SMAP1, SMAP2 exhibits GAP activity and interacts with clathrin heavy
chain (CHC). Furthermore, we show that SMAP2 interacts with the clathrin assembly protein CALM. Unlike SMAP1,
however, SMAP2 appears to be a regulator of Arf1 in vivo, because cells transfected with a GAP-negative SMAP2 mutant
were resistant to brefeldin A. SMAP2 colocalized with the adaptor proteins for clathrin AP-1 and EpsinR on the early
endosomes/trans-Golgi-network (TGN). Moreover, overexpression of SMAP2 delayed the accumulation of TGN38/46
molecule on the TGN. This suggests that SMAP2 functions in the retrograde, early endosome-to-TGN pathway in a
clathrin- and AP-1–dependent manner. Thus, the SMAP gene family constitutes an important ArfGAP subfamily, with
each SMAP member exerting both common and distinct functions in vesicle trafficking.
INTRODUCTION
Clathrin-mediated vesicle formation is an essential step in
the intracellular trafficking of membrane compartments. The
locations in the cell at which vesicles are formed are regu-
lated by various factors in a highly complex manner. AP-1
and AP-2 are tetrameric adaptors for clathrin and recruit it
to sites of vesicle budding (specifically, the trans-Golgi net-
work (TGN)/endosome and plasma membrane, respectively;
Hirst and Robinson, 1998; Lewin and Mellman, 1998; Scales et
al., 2000). Thereafter, monomeric adaptor proteins such as
AP180 and CALM induce clathrin assembly, thereby generat-
ing clathrin-coated vesicles (Hao et al., 1999; Tebar et al., 1999;
Ford et al., 2001). Subsequently, the budded vesicles fuse to the
acceptor membrane where Hsc70 and auxilin disassemble the
clathrin coat (Cremona, 2001; Lemmon, 2001; Morgan et al.,
2001; Fotin et al., 2004).
Studies on clathrin have mainly focused on secretion from
the TGN and endocytosis from the plasma membrane. How-
ever, recent studies revealed that clathrin is also an indis-
pensable coat component of vesicles that bud from the en-
dosome (Meyer et al., 2000; Rohn et al., 2000; Hinners and
Tooze, 2003). One endosome-to-TGN pathway utilizes AP-1
as a tetrameric adaptor for clathrin. In addition, monomeric
adaptor proteins such as EpsinR, TIP47, and PACS-1 are
responsible for selecting cargo proteins in endosome-to-
TGN transport (Diaz and Pfeffer, 1998; Wan et al., 1998;
Saint-Pol et al., 2004). For example, one early endosome-to-
TGN pathway that transports TGN38 and Shiga toxin is
regulated by EpsinR. In contrast, a late endosome-to-TGN
pathway that transports mannose-6-phosphate receptor and
furin convertase is regulated by TIP47 and PACS-1.
Vesicle formation not only requires the abovementioned
vesicle components (namely, clathrin and its adaptors) but
also enzymatic activity. This is supplied by small GTPase
ADP-ribosylation factor (Arf; Nie et al., 2003b). Like other
small GTPases, Arf cycles between a GTP-bound active state
and a GDP-bound inactive state. Its activation and inactiva-
tion are regulated by guanine-nucleotide exchange factor
(GEF) and GTPase-activating protein (GAP), respectively
(Randazzo and Hirsch, 2004; Shin and Nakayama, 2004). The
six Arfs are classified into three groups: Arf1, 2, and 3 are
class I, Arf4 and 5 are class II, and Arf6 is class III. Among
them, Arf1 functions on the Golgi/TGN/endosome. In its
active state, Arf1 recruits coat and adaptor proteins such as
COPI, AP-1, and AP-3 to the membrane and induces the
assembly and nucleation of coated vesicles (Donaldson et al.,
1991; Serafini et al., 1991; Traub et al., 1993; Ooi et al., 1998).
This localization of the coat/adaptor proteins is sensitive to
brefeldin A (BFA) because BFA inactivates Arfs of classes I
and II by inhibiting the interaction between Arf and its GEF
(Donaldson et al., 1992; Peyroche et al., 1999). Therefore,
treatment of cells with BFA causes the disintegration of the
Golgi complex and tubulation of the endosomal membrane.
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In contrast, Arf6 regulates the endocytosis of vesicles from
the plasma membrane and the recycling of endosome to the
plasma membrane (Donaldson, 2003), and the GEFs for
Arf6, ARNO, and EFA are insensitive to BFA (Franco et al.,
1999; Peyroche et al., 1999).
The ArfGAP family also contains several members and to
date 16 mammalian genes have been reported (Bernards,
2003; Randazzo and Hirsch, 2004). Importantly, it appears
that distinct Arf and ArfGAP combinations participate in
different intracellular vesicle transport pathways. For exam-
ple, GAP1 is an Arf1GAP that forms a complex with COPI in
an Arf1-dependent manner (Liu et al., 2005) and interacts
directly with its cargo protein, a KDEL receptor (Aoe et al.,
1999). This interaction is essential for the sorting of cargo
proteins into COPI-coated vesicles on the Golgi complex. In
contrast, AGAP1, another Arf1GAP, interacts with AP-3 and
functions in a late endosome-to-lysosome pathway (Nie et
al., 2003a). Moreover, we recently identified SMAP1 as a
novel Arf6GAP (Tanabe et al., 2005). SMAP1 interacts with
clathrin and regulates the clathrin- and AP-2–dependent
endocytosis of transferrin receptors from the plasma mem-
brane.
In this study, we identified a homologue of SMAP1 that
we named SMAP2. Like SMAP1, SMAP2 possesses a GAP
domain and interacts with clathrin heavy chain (CHC). Fur-
thermore, we show that SMAP2 interacts with the clathrin
assembly protein CALM. Unlike SMAP1, however,
SMAP2 appears to be a regulator of Arf1 and is involved
in clathrin- and AP-1– dependent trafficking in the early
endosome-to-TGN pathway. Thus, the SMAP gene family
constitutes an important ArfGAP subfamily and each
SMAP member exerts common as well as distinct func-
tions in vesicle trafficking.
MATERIALS AND METHODS
Cells, Reagents, and Antibodies
HeLa and Cos-7 cells were cultured in DMEM containing 10% (vol/vol) fetal
calf serum. BFA was purchased from Sigma-Aldrich (St. Louis, MO). The
following antibodies were purchased: the anti-influenza hemagglutinin (HA)
rat monoclonal antibody (mAb) 3F10 was from Roche Diagnostics (Indianap-
olis, IN), the mouse mAbs against c-Myc (9E10) and AP-1 (-adaptin, 100/3)
were from Sigma-Aldrich, the mouse mAbs against CHC (X22) and AP-2 (-
adaptin, AP.6), and the rabbit polyclonal antibodies (pAb) against -COP and
furin convertase were from Affinity BioReagents (Golden, CO), the mouse mAb
against AP-3 (-adaptin) was from Transduction Laboratories (Lexington, KY),
the anti-CD25 mouse mAb (7G7/B6) was from Upstate Biotechnology (Lake
Placid, NY), the anti-TGN46 sheep pAb was from Serotec (Oxford, United
Kingdom), the anti-6His mouse mAb was from Clontech Laboratories (Palo Alto,
CA), the Cy3-conjugated goat anti-rat IgG was from Chemicon (Temecula, CA),
and the Alexa488-conjugated goat anti-mouse and anti-rabbit IgGs, Alexa488-
conjugated donkey anti-sheep IgG and Alexa488-conjugated human-transferrin
were from Molecular Probes (Eugene, OR).
Plasmid Construction
A fragment that corresponds to a portion of BC052413 (GenBank/NCBI) was
PCR-amplified from cDNA from a murine erythroleukemic cell line. By using
this fragment as a hybridization probe, we screened a cDNA library prepared
from the same cells and obtained cDNA clones encoding SMAP2. A cDNA
encoding CALM was isolated from the same cDNA library by a PCR method.
The various mutations described below were introduced into the coding
region of SMAP2 by a PCR method. cDNAs encoding rat GAP1, murine
SMAP1, Arf1, and Arf6 were isolated as described previously (Tanabe et al.,
2005). TGN38 cDNA was isolated from murine liver-derived cDNA by a PCR
method. The human CHC, GGA1, and CD25 cDNAs were provided by Drs. T.
Nagase, K. Nakayama, and H. Asao, respectively. The human furin conver-
tase (79823) and EpsinR (KIAA0171) cDNAs were obtained from ATCC and
the Kazusa DNA Research Institute, respectively. A chimeric gene encoding
an extracellular domain of CD25 fused to the transmembrane and cytoplasmic
domains of TGN38 was constructed by a PCR method.
To express these cDNAs in mammalian cells, they were inserted into
pcDNA3 (Invitrogen, Carlsbad, CA). For immunodetection, each protein was
tagged with the epitope at its amino-terminus as follows: HA-SMAP2, Myc-
SMAP2, HA-GAP1, Myc-CALM, Myc-EpsinR, Myc-GGA1, and Myc-furin
convertase.
Yeast Two-Hybrid Screening
The Matchmaker Two-Hybrid System 3 (Clontech Laboratories) was used
according to the instructions in the manufacturer’s manual. The bait plasmid
was constructed by inserting the murine SMAP2 cDNA next to the GAL4
DNA-binding domain of the vector pGBKT7. A cDNA library prepared from
murine brain was fused to the GAL4 DNA-activation domain of the vector
pGADT7 and served as the source of prey plasmids. AH109 cells were used
as host cells. The selective medium was devoid of Trp, Leu, His, and Ade and
added by 2.5 mM 3-amino-1,2,4-triazole. Plasmid DNAs were recovered from
positive clones and sequenced by using an ABI PRISM 310 genetic analyzer
(Applied Biosystems, Foster City, CA).
Preparation of Recombinant Proteins
To express cDNAs in bacteria, they were inserted into pGEX5X-3 (Amersham
Pharmacia Biotech, Piscataway, NJ). The sequences expressed were the amino-
terminal 163 residues of SMAP2, the amino-terminal 255 residues of SMAP1, the
amino-terminal 246 residues of GAP1, and the entire coding sequences of Arf1
and Arf6. All were fused at their amino-termini to glutathione S-transferase
(GST) and tagged with hexahistidines at their carboxy-termini.
Recombinant proteins were prepared as described previously (Tanabe et al.,
2005). Briefly, the Escherichia coli strain BL21 was transformed with one of the
expression plasmids and cultured in LB medium containing ampicillin. Iso-
propyl--d-thiogalactoside was then added at 0.4 mM to induce protein
expression. The cells were harvested, and the GST fusion proteins were
purified by using a B-PER GST-spin purification kit (Pierce Chemical, Rockford,
IL). The fusion protein was digested with Factor Xa (Novagen, Madison, WI) and
the GST-free protein was purified by using a 6*His spin purification kit (Pierce
Chemical). The protein concentrations were assayed by a BCA protein assay kit
(Pierce Chemical). The purity of the recovered proteins was 95% as judged by
SDS-PAGE.
GAP Assay
GAP assays were performed as described in our previous study (Tanabe et al.,
2005). Briefly, recombinant nonmyristoylated Arf1 or Arf6 proteins were
loaded with [-32P] GTP, and GTP hydrolysis was initiated by the addition of
GAP for the indicated time. The reaction was then terminated and unbound
nucleotides were removed. GTP and GDP were eluted from the Arf protein
and separated by TLC. The plate was exposed to a phosphorimager screen
and radioactivity was detected by a Bio Imaging Analyzer (Fuji Photo Film,
Tokyo, Japan).
Immunoprecipitation Analysis
Cos-7 cells were transfected with the SMAP2 expression plasmid using Ef-
fectene (QIAGEN, Chatsworth, CA) and incubated for 24 h at 37°C. The cells
were then lysed with a buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 1% (vol/vol) Nonidet P-40, and a mixture of protease
inhibitors (Complete; Roche Diagnostics). The cell lysate was precleared by
protein G-Sepharose beads (Amersham Pharmacia) and then incubated with
the primary antibody, and the immunoprecipitates were adsorbed to the
beads. The beads were washed five times with lysis buffer in which the
concentration of NaCl was raised to 200 mM. Proteins were eluted by boiling
the beads in SDS sample buffer. Gel electrophoresis of the proteins, transfer of
the proteins from the gel to a filter, and immunoreaction with the secondary
antibody were performed as described previously (Chiba et al., 1997). Prod-
ucts were visualized by use of the ECL Plus reagent (Amersham Pharmacia).
Immunofluorescence Microscopy
Cos-7 or HeLa cells on coverslips were transfected with plasmid DNA using
Effectene and incubated for 24 h at 37°C. They were then fixed with 4%
(wt/vol) paraformaldehyde in phosphate-buffered saline (PBS) for 15min at
room temperature (RT), washed three times with PBS, and blocked with 1%
(wt/vol) bovine serum albumin and 0.1% Triton X-100 in PBS for 15 min at
RT. In some cases, the transfected cells were treated with 5 g/ml BFA for 2
min before fixation. The fixed cells were incubated with appropriately diluted
primary and then secondary antibodies for 45 min each at RT. After washing
with PBS, the coverslips were mounted on slide glasses using Vectashield
(Vector Laboratories, Burlingame, CA) and observed with a confocal micro-
scope (LSM-401, Zeiss, Thornwood, NY). To detect the internalization and
transport of transferrin or CD25-TGN38, cells were rinsed with PBS and
preincubated in 0.1% (wt/vol) bovine serum albumin in DMEM for 30 min at
37°C. The cells were then incubated at 37°C with 25 g/ml Alexa488-conju-
gated human transferrin or 10 g/ml anti-CD25 mAb for the indicated time,
rinsed with PBS, fixed, and processed for immunofluorescence as described
above.
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RESULTS
Identification of SMAP2 and Its Domain Structure
To identify a homologue of the murine SMAP1 gene, we
searched by BLAST the GenBank/NCBI database. We found
that the SMAP1-like protein BC052413 was the only one
detected in the database as showing a high degree of ho-
mology to SMAP1 over the entire length. We then screened
a cDNA library prepared from a murine erythroleukemic
cell line for the gene encoding BC052413 and obtained sev-
eral cDNA clones. The longest contained a 2871 base pairs
insert and its sequence exactly matched that of BC052413
(unpublished data). We named this gene SMAP2.
The polypeptide encoded by SMAP2 is composed of 428
aa residues and has a predicted molecular mass of 47 kDa.
The alignment of the aa sequences of SMAP2 and SMAP1 is
shown in Figure 1A. SMAP2 and SMAP1 share 50% overall
sequence homology but four distinct regions in SMAP2,
namely, aa 16-125, aa 173-212, aa 244-277, and aa 369-428,
show a marked degree of conservation with SMAP1 (85, 74,
69, and 48% homology, respectively; Figure 1B). As de-
scribed in the following sections, we sought to determine the
functions of these conserved regions.
Detection of GAP Activity Mediated by SMAP2
The amino-terminal region (aa 16-125) of SMAP2 harbors a
conserved CX2CX16CX2C zinc finger motif and is strongly
homologous to the corresponding region of SMAP1. There-
fore, it is possible that SMAP2, like SMAP1, exhibits ArfGAP
activity. We tested this possibility by incubating SMAP2
together with Arf1 or Arf6 as a substrate. The SMAP2 pro-
tein we used for this purpose was the truncated aa 1-163
segment of SMAP2 that was purified from a bacterial cell
lysate (the intact form was insoluble when expressed in
bacteria). As shown in Figure 2A, SMAP2 mediated the
hydrolysis of GTP that had been loaded onto both Arf1 and
Arf6. Similarly, SMAP1, which is an Arf6-specific GAP in
vivo, and GAP1, which is an Arf1-specific GAP in vivo,
showed GAP activity with both Arf1 and Arf6 in these in
vitro assays. The extent of GTP hydrolysis mediated by
SMAP2 was found to be dependent on the amount of
SMAP2 protein added and the length of the incubation
reaction (Figure 2, B and C). The 50th residue of GAP1 (an
arginine) is known to be vital for its GAP activity (Szafer et
al., 2000) and is also conserved in SMAP2 as the 56th residue.
When this R56 residue was replaced with glutamine, it
Figure 1. The aa sequence of the SMAP2
protein and depiction of its functional do-
mains. (A) Alignment of the aa sequences of
the SMAP2 and SMAP1 proteins. The aa se-
quence of SMAP2 has been predicted as
BC052413, which is registered in GenBank/
NCBI. We authenticated the sequence of
BC052413 by independently isolating and se-
quencing cDNA clones. The aa sequence of
SMAP1 has been described in our previous
study (Tanabe et al., 2005). SMAP2 and SMAP1
encode 428 and 440 aa proteins, respectively.
Their identical aa residues are indicated by
white letters on a black background. The clas-
sical and atypical CHC-binding motifs corre-
spond to LLGLD (aa 187-191) and DLL (aa
212-214), respectively. (B) Functional do-
mains of the SMAP2 protein. These do-
mains include a GAP activity domain (aa
1-163), a clathrin-interacting domain (aa
163-231), and a CALM-interacting domain
(aa 339-395). The regions that are highly
conserved between SMAP2 and SMAP1,
namely, the aa 16-125, aa 173-212, aa 244-
277, and aa 369-428 regions, are also indicated (by bars). The aa numbers refer to those in SMAP2.
Figure 2. GAP activity of SMAP2 on Arf1 and Arf6.
(A) Comparison of the GAP activity of SMAP2 with
that of SMAP1 and GAP1. Six micrograms each of the
SMAP2 (aa 1-163), SMAP1 (aa 1-255), or GAP1 (aa
1-246) proteins were incubated in vitro with 1 g of
GTP-loaded Arf1 or Arf6 for 60 min. In “mock,” no
GAP was added to the reaction. After separating the
GDP from GTP on thin-layer chromatograms, the de-
gree of GTP hydrolysis was calculated. This is shown as
a percentage of GDP over GDPGTP. Each reaction
was independently performed three times and the av-
erages as well as SD values are shown. (B and C) Con-
centration- and incubation time–dependent GAP activ-
ity of the SMAP2 protein. Six () or 3 g (●) of SMAP2
protein, or 6 g of mutated SMAP2R56Q protein (‚)
were incubated with 1 g of GTP-loaded Arf1 (B) or
Arf6 (C) for the indicated times. After separating the GDP from GTP on thin-layer chromatograms, the degree of GTP hydrolysis was calculated
and is shown as a percentage as in A. Each data point shows the averages and SD values of three independent experiments.
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reduced or abolished the GAP activity of SMAP2. Therefore,
domain aa 1-163 of SMAP2 was determined to have ArfGAP
activity (Figure 1B).
Identification of a Clathrin-interacting Domain in SMAP2
The second conserved region of SMAP2 is contained by aa
173-212. This region harbors both classical and atypical
CHC-binding motifs such as LLGLD (aa 187-191) and DLL
(aa 212-214), respectively (Figure 1A). We previously re-
ported that the LLGLD motif in SMAP1 functions as a
CHC-binding motif (Tanabe et al., 2005; note that a DLL
motif is not conserved in SMAP1). We therefore examined
whether SMAP2 also binds CHC (Figure 3A). Thus, Cos-7
cells were transfected or not with SMAP2 tagged with a
Myc-epitope, and the cell lysate was immunoprecipitated
with anti-CHC antibody (top panel). Probing of the filter
with anti-Myc antibody revealed that the transduced
SMAP2 was coimmunoprecipitated by the anti-CHC anti-
body. Conversely, when cells were transfected with SMAP2
tagged with HA, CHC was coimmunoprecipitated by the
anti-HA but not the irrelevant anti-Myc antibodies (bottom
panel). This indicates the SMAP2 and CHC molecules phys-
ically associate inside the cells. In addition, replacement of
all the residues in both LLGLD and DLL motifs by alanine
Figure 3. Interaction of SMAP2 protein with the clath-
rin molecule. (A) Coimmunoprecipitation of SMAP2
and CHC. Cos-7 cells were transfected with Myc-
SMAP2, HA-SMAP2, or HA-SMAP2CBm as indicated,
and their cell lysates were immunoprecipitated (IP) by
anti-Myc, anti-HA, or anti-CHC antibodies as indicated.
The precipitates were then subjected to electrophoresis,
transferred to a filter, and probed by the indicated
antibody (IB). (B) Subcellular localization of the SMAP2
and CHC proteins. Cos-7 cells were transfected with
cDNAs encoding the SMAP2 (aa 1-428), with deletion
mutants of SMAP2 that corresponded to aa 163-428 or
aa 231-428, or with the CBm mutant of SMAP2, respec-
tively. In the CBm mutant, all the aa residues in the
LLGLD (aa 187-191) and DLL (aa 212-214) motifs were
replaced by alanine. The cells were then fixed and sub-
jected to double immunofluorescence analysis. The HA-
tagged SMAP2 and its mutant proteins were detected
by anti-HA antibody (red fluorescence), whereas the
endogenous clathrin molecules were detected by anti-
CHC antibody (green fluorescence). Merged images are
shown in the right-hand column. In the insets, portions
of the cells are enlarged.
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abolished the coimmunoprecipitation of CHC (see the lane
of SMAP2CBm). Thus, the LLGLD and DLL motifs are es-
sential for SMAP2 to interact with CHC. It must be noted
that, unlike the case of SMAP1, mutation of the sole LLGLD
motif was not sufficient to disrupt the association of SMAP2
with CHC (unpublished data).
We next examined the subcellular localization of SMAP2
and CHC by double immunofluorescence analysis (Figure
3B). Thus, Cos-7 cells were transfected with SMAP2 (1-428)
tagged with HA and subjected to immunofluorescence stain-
ing. The transduced SMAP2 protein was detected by anti-
HA antibody, whereas endogenous CHC was detected by
anti-CHC antibody. SMAP2 was detected as multiple, ag-
gregate-like structures in the cytoplasm and most of the
CHC-derived fluorescence overlapped with that of SMAP2.
We then analyzed the two deletion-type mutants of SMAP2
that corresponded to aa 163-428 and aa 231-428, respectively.
CHC overlapped with the aggregates formed by the aa
163-428. On the other hand, the aa 231-428 of SMAP2 also
formed aggregates but CHC did not overlap with them. In
addition, the introduction of CBm mutation abolished the
aggregate formation of SMAP2 (1-428) with CHC. Therefore,
the aa 163-231 region that harbors the LLGLD and DLL
motifs is necessary for SMAP2 to form aggregates and over-
lap with CHC. The apparent overlap of SMAP2CBm- and
CHC-fluorescence at a jutxtanuclear region reflects the TGN
as shown below. Probably, SMAP2-CBm and CHC localized
to this structure simultaneously and independently. Deter-
mination of aa motif, if any, that is responsible for the
subcellular localization of SMAP2 needs a separate study.
Collectively, the immunofluorescent results complement
those of immunoprecipitation. Thus, based on both, we des-
ignate the aa 163-231 region a clathrin-interacting domain
(Figure 1B).
Identification of the CALM-interacting Domain in SMAP2
The other two conserved regions, namely, aa 244-277 and aa
369-428, did not show any significant homology to known
motifs or domains when we performed BLAST and SMART
domain analysis. Therefore, to determine the functions of
these regions, we sought to identify molecules that may
interact with them by yeast two-hybrid analysis. SMAP2
lacking the amino-terminal aa 1-130 was used as a bait and
the prey was a cDNA library prepared from a murine brain.
Screening of four million independent clones yielded several
positive clones, including a cDNA that encodes a portion of
the CALM protein. Consequently, a cDNA clone that har-
bors the entire CALM protein was reisolated from a library
and used in the following studies. This clone was first used
to confirm that intact SMAP2 (aa 1-428) and CALM proteins
indeed interact in yeast cells (Figure 4A). We then tried to
define the CALM-interacting domain in SMAP2 and trans-
Figure 4. Interaction of SMAP2 with CALM. (A) SMAP2 was tested for its ability to interact with CALM. Yeast cells were cotransformed
by the indicated combinations of bait (pGBKT7) and prey (pGADT7) vectors and grown on nonselective (Trp, Leu) and selective (Trp,
Leu, His, Ade, 2.5 mM 3-amino-1,2,4-triazole) media, respectively. The cDNAs tested were the intact SMAP2 (aa 1-428), a portion of
SMAP2 (aa 339-428), and the intact CALM, respectively. (B) Subcellular localization of SMAP2 and CALM proteins. Cos-7 cells were
cotransfected with CALM and SMAP2 (aa 1-428) or deletion mutants of SMAP2 that corresponded to aa 163-395 or aa 339-428, respectively,
fixed, and processed for double immunofluorescence analysis. The HA-tagged SMAP2 or deletion proteins were detected by anti-HA
antibody (red fluorescence), whereas the Myc-tagged CALM protein was detected by anti-Myc antibody (green fluorescence). Merged images
are shown in the right-hand column. In the insets, portions of the cells are enlarged.
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duced into yeast cells a portion of SMAP2 that consisted of
aa 339-428. This region also interacted with CALM. The
observed interaction was specific, because no colony grew
on a selective medium if either the bait or prey plasmid
harbored no cDNA insert.
We then examined the subcellular localization of the
SMAP2 and CALM proteins by double immunofluorescence
(Figure 4B). Thus, Cos-7 cells were cotransfected with HA-
tagged SMAP2 (aa 1-428) and Myc-tagged CALM and sub-
jected to immunofluroescence analysis. The two proteins
colocalized as multiple aggregates in the cytoplasm. Cos-7
cells were transfected as well with deletion-type mutants of
SMAP2 that consisted of aa 163-395 and aa 339-428. Both
SMAP2 mutants colocalized with CALM. Thus, the aa 339-395
region in SMAP2 is a putative CALM-interacting domain.
In summary, as shown in Figure 1B, the SMAP2 protein
harbors three distinct domains that are responsible for GAP
activity, clathrin interaction, and CALM interaction, respec-
tively. The functional significance of the remaining con-
served region (aa 244-277) is not known at present.
Subcellular Localization of SMAP2 Protein
In the above experiments of cDNA transfection, we used Cos-7
cells in which transduced SMAP2 was excessively produced
and appeared to form aggregates. This was convenient to show
whether SMAP2 interacts with CHC or CALM by immunohis-
tochemistry. However, aggregate-like structures are not likely
to represent the physiological distribution of SMAP2 inside the
cell. The anti-SMAP2 antibody we generated was useful to
detect the endogenous protein only by immunoblot but not
immunofluorescence (Supplementary Figure S1). Therefore,
we transfected HeLa cells with an HA-tagged intact SMAP2; in
this case, the SMAP2 protein expression level was moderate
(Figure 5). This revealed that SMAP2 was distributed on mul-
tiple dotlike as well as juxtanuclear structures. Staining for
endogenous CHC displayed a similar pattern to that of
SMAP2, and at least some of the CHC fluorescence colocalized
with that of SMAP2. However, SMAP2 did not overlap with
endogenous COPI, which is a coatmer protein that forms ves-
icles on the Golgi apparatus.
SMAP2 and Clathrin Adaptors
Because SMAP2 colocalizes with CHC, we examined which
clathrin adaptors are utilized by SMAP2. There are two
distinct classes of clathrin adaptors denoted as AP-1 and
AP-2. Each adaptor functions in a different pathway of clath-
rin-mediated vesicle transport. AP-1 functions on the early
endosome/TGN, whereas AP-2 does on coated pits on the
plasma membrane. AP-3 is a third class of adaptor and it is
not known whether AP-3 involves clathrin in vivo. This
AP-3 functions on the late endosome. We compared the
distribution of transduced intact SMAP2 with that of each
endogenous adaptor by double immunofluorescence analy-
sis (Figure 6). The SMAP2 staining significantly overlapped
that of AP-1, whereas overlap of SMAP2 with either AP-2 or
AP-3 was minimum.
EpsinR, a monomeric adaptor for clathrin, has been iden-
tified as a factor that binds to AP-1 and appears to be
utilized in early endosome-to-TGN transport (Saint-Pol et
al., 2004). To test whether SMAP2 also overlaps with EpsinR,
HeLa cells were cotransfected with HA-SMAP2 and Myc-
EpsinR. We found that EpsinR staining colocalized with that
of SMAP2. In contrast, HA-SMAP2 did not colocalize with
Myc-GGA1, a clathrin-adaptor protein that is utilized in a
TGN-to-endosome pathway (Ghosh and Kornfeld, 2004).
Thus, SMAP2 is probably involved in AP-1– and EpsinR-
Figure 5. Subcellular localization of SMAP2 and coat proteins. HeLa cells were transfected with HA-SMAP2 (aa 1-428), fixed, and processed
for double immunofluorescence analysis. SMAP2 was detected by anti-HA antibody (red fluorescence), whereas endogenous CHC or COPI
were detected by their respective specific antibodies (green fluorescence). Merged images are shown in the right-hand column. In the insets,
portions of the cells are enlarged.
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mediated vesicle transport. The multiple dot-like fluores-
cence likely represents the SMAP2 located on the early en-
dosomes, whereas the juxtanuclear fluorescence probably
reflects the SMAP2 on endosomes that were located adjacent
to the TGN and could not be distinguished from the TGN
itself by optical microscopy.
SMAP2 Functions on Arf1 In Vivo
We have shown so far that SMAP2 colocalizes with clathrin,
AP-1, and EpsinR on the early endosome/TGN. Judging
from its subcellular localization, SMAP2 probably acts as an
Arf1GAP in the cell. However, our in vitro GAP assays
showed that SMAP2 was equally active with both Arf1 and
Arf6 (Figure 2A). Thus, in this section, we examined
whether SMAP2 acts on Arf1 in vivo by transfecting HeLa
cells with HA-tagged SMAP2R56Q, a GAP-negative mutant.
The cells were then processed for double immunofluores-
cence analysis (Figure 7A). In drug-untreated cells, regard-
less of the SMAP2R56Q expression, endogenous AP-1 was
detected on the endosome/TGN as shown above. The trans-
Figure 6. Subcellular localization of SMAP2
and clathrin adaptors. HeLa cells were trans-
fected with HA-SMAP2 (aa 1-428), fixed, and
processed for double immunofluorescence
analysis. SMAP2 was detected by anti-HA
antibody (red fluorescence), whereas AP-1,
AP-2, AP-3, EpsinR, and GGA1 were detected
by their respective specific antibodies (green
fluorescence). AP-1, AP-2, and AP-3 are en-
dogenous molecules while EpsinR and GGA1
are the transfected Myc-EpsinR and Myc-
GGA1 molecules, respectively. Merged im-
ages are shown in the right-hand column. In
the insets, portions of the cells are enlarged. It
must be noted that the juxtanuclear struc-
tures seen in Figure 5 were out of focus in the
SMAP2 photos here.
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fected cells were then treated by BFA, an inhibitor of Arf1. In
the cells that were not transduced by SMAP2R56Q (indi-
cated by arrowheads), the accumulation of AP-1 on the
endosome/TGN was no longer seen, and the AP-1–derived
fluorescence was dispersed and abolished. This confirms
that the accumulation of AP-1 on the endosome/TGN is an
Arf1-dependent process. In contrast, in the SMAP2R56Q-
expressing cells (indicated by arrows), the accumulation of
AP-1 on membranes persisted and was resistant to BFA
treatment. Arf1 in such cells may remain as a GTP-bound
form on membranes where SMAP2 is normally the primary
ArfGAP. Possible mechanisms how SMAP2R56Q could lead
the differently localized AP-1 to become resistant to BFA are
discussed later. In any case, the above observations indicate
that SMAP2 is likely to function in an Arf1 (and/or the other
Arf of classes I and II)-dependent process that involves the
endosome.
Because Arf1 is involved in vesicle transport on the Golgi
complex as well, we also examined whether SMAP2 partic-
ipates in this pathway. COPI is a coat protein that is utilized
in Arf1-dependent vesicle transport and is detected on the
Golgi complex. Treatment of cells with BFA abolished the
accumulation of COPI, but this was not affected by the expres-
sion of SMAP2R56Q (Figure 7B). As a control, the cells were
transfected with a GAP-negative mutant of GAP1, GAP1C45A.
This rendered the accumulation of COP1 on the Golgi complex
resistant to BFA (Figure 7C). Thus, SMAP2 is probably not
involved in COP1- and Arf1-dependent vesicle transport on
the Golgi complex. The accumulation of AP-3 on the late en-
dosome was also abolished by the BFA treatment of cells,
irrespective of the SMAP2R56Q expression (unpublished data).
This strengthens that SMAP2 is not likely involved in AP-3-
dependent transport on the late endosome.
Cargo Protein Candidates in the SMAP2-mediated
Pathways
We searched which molecules are likely to be transported by
the SMAP2-mediated pathways. Judging from the subcellu-
lar localization of SMAP2 on the early endosome/TGN,
likely candidates are human TGN46 or murine TGN38 (the
two are orthologous proteins). Thus, HeLa cells were doubly
stained for endogenous TGN46 and the transfected intact
HA-SMAP2 protein (Figure 8A). At least some of the TGN46
proteins colocalized with SMAP2 on the TGN. Because en-
dogenous TGN46 was mainly detected on the TGN and not
the endosome, we also analyzed cells cotransfected with
SMAP2 and CD25-tagged TGN38 (Figure 8B). The fluores-
cence of TGN38 on the early endosome overlapped with that
of SMAP2. These results suggest that TGN38/46 is a likely
cargo protein via a SMAP2-dependent process.
Transferrin receptors are constitutively endocytosed from
the plasma membrane to the early endosome. Although the
residence of transferrin receptors on the early endosome is
temporary because of their recycling to the plasma mem-
brane, SMAP2 might partially colocalize with incorporated
transferrin receptors. To test this, HeLa cells were transfected
Figure 7. Effect of SMAP2R56Q expression and BFA treatment on the subcellular distribution of AP-1 and COPI. HeLa cells were transfected
with HA-SMAP2R56Q (aa 1-428; A and B) or HA-GAP1C45A (C), treated with or without BFA, and then fixed and processed for double
immunofluorescence analysis. SMAP2R56Q or GAP1C45A were detected by anti-HA antibody, whereas endogenous AP-1 or COPI were
detected by their respective specific antibodies. The arrows and arrowheads indicate SMAP2R56Q-expressing and nonexpressing cells,
respectively.
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with SMAP2 and incubated with dye-conjugated transferrin
(Figure 8C). Indeed, we found SMAP2 and transferrin recep-
tors colocalized to some degree on the early endosome.
We also found that furin convertase, which is transported
from the late endosome to the TGN (Rohn et al., 2000), is not
likely to be a cargo protein carried by a SMAP2-dependent
Figure 8. Subcellular localization of SMAP2 and its possible cargo protein. (A) HeLa cells were transfected with HA-SMAP2 (aa 1-428),
fixed, and processed for double immunofluorescence analysis. SMAP2 was detected by anti-HA antibody (red fluorescence), whereas
endogenous human TGN46 was detected by anti-TGN46 antibody (green fluorescence). (B) HeLa cells were cotransfected with HA-SMAP2
and the chimeric CD25-murine TGN38 molecule, fixed, and processed for double immunofluorescence analysis. SMAP2 (red fluorescence)
and CD25-TGN38 (green fluorescence) were detected by their respective specific antibodies. (C) HeLa cells were transfected with HA-SMAP2,
incubated with dye-conjugated transferrin, fixed, and processed for double immunofluorescence analysis. SMAP2 was detected by anti-HA
antibody (red fluorescence), whereas transferrin was visible as green fluorescence. (D) HeLa cells were cotransfected with HA-SMAP2 and
Myc-furin convertase, fixed, and processed for double immunofluorescence analysis. SMAP2 and furin convertase were detected by anti-HA
antibody (red fluorencence) and anti-Myc antibody (green fluorescence), respectively. In A–D, merged images are shown in the right-hand
column. In the insets, portions of the cells are enlarged.
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pathway, because cotransfected SMAP2 and furin conver-
tase did not colocalize at all (Figure 8D).
Overexpression of SMAP2 Delays the Transport
of CD25-TGN38
Finally, we assessed directly whether overexpression of
SMAP2 affects the transport of CD25-TGN38 protein from
the early endosome to the TGN. Cos-7 cells were cotrans-
fected with HA-SMAP2 and CD25-TGN38 and incubated
with anti-CD25 antibody, which triggers the internalization
of the chimeric molecule. After the incubation, the cells were
fixed and processed for double immunofluorescence (Figure
9). The photos presented in the panels A to F represent the
cells after 15 min incubation. The TGN38 protein appeared
Figure 9. Effect of SMAP2 overexpression on
the transport of CD25-TGN38 molecule. Cos-7
cells were cotransfected by either one of HA-
SMAP2 (A and B), HA-SMAP2R56Q (C and
D), or HA-SMAP2CBm (E and F) together
with the CD25-TGN38 chimeric cDNA. The
cells were then incubated for 15 or 45 min
with the anti-CD25 antibody that triggers the
internalization of the chimeric molecule. The
cells were fixed and processed for double im-
munofluorescence. In A, C, and E, the SMAP2
protein was detected by the anti-HA anti-
body, whereas the chimeric protein was de-
tected by the anti-CD25 antibody in B, D, and
F. The photos presented in A to F represent
the cells after 15 min incubation. The arrows
indicate the SMAP2-expressing cells. In G,
among the 100 cells that were positive for the
SMAP2 staining, the numbers of cells that
showed the TGN accumulation or no accumu-
lation of TGN38 were counted, respectively. The
percent inhibition corresponds to the cells that
were SMAP2-positive but did not accumulate
TGN38 at the TGN. Independent transfections
were repeated three times, and the averages and
SD values of percent inhibition are shown. In a
separate experiment, we confirmed by immuno-
blot analysis that the expression level of HA-
SMAP2, HA-SMAP2R56Q, and HA-SMAP2CBm
did not vary significantly among the transfected
cells.
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to reach and accumulate on the TGN in the untransduced
cells, whereas the protein remained on the endosomes and
did not reach the TGN in the SMAP2-transduced cells (in-
dicated by arrows in A and B). We counted the number of
cells that showed or did not show the TGN accumulation of
TGN38, respectively. Among the SMAP2-transduced cells,
the inhibition of TGN-accumulation was as high as 35% (see
the lane of SMAP2 at 15 min in panel G). In contrast, TGN38
reached the TGN in most of mock-transfected cells (see the
inhibition of only 4%). Thus, overexpression of intact
SMAP2 significantly impairs the transport of CD25-TGN38
from the early endosome to the TGN.
We then examined the effects of each R56Q or CBm mu-
tation on the above described inhibitory activity of SMAP2.
The R56Q mutation reduced the inhibition of TGN-accumu-
lation to 20% (see the lane of SMAP2R56Q at 15 min in panel
G) and thus the TGN38 molecule could now reach the TGN
(indicated by arrows in the panels C and D). On the other
hand, the CBm mutation rather enhanced the inhibitory
activity of SMAP2–50% (see the lane of SMAP2CBm at 15
min in panel G) and therefore the TGN38 molecule re-
mained on the endosomes and did not accumulate on the
TGN (indicated by arrows in panels E and F). This stronger
inhibitory activity of SMAP2CBm on the transport was ev-
ident even after the prolonged incubation of cells to 45 min
(see the 35% inhibition in the panel G). At this time, most of
TGN molecule appeared to reach the TGN in the wild-type
as well as R56Q-transduced cells (note that their inhibitions
that were 10%).
Possible mechanisms that might explain the differential
effects caused by the wild-type as well as mutated SMAP2
proteins are discussed below. At this moment, we conclude
that SMAP2 can function in a retrograde transport of CD25-
TGN38 from the early endosome to the TGN.
DISCUSSION
In this study, we identified SMAP2 as a novel ArfGAP that
shows a high degree of homology with SMAP1. Further-
more, we demonstrated that SMAP2 prefers Arf1 in vivo
and interacts with both CHC and CALM. SMAP2 is the first
example of an ArfGAP that is located on the early endosome
together with AP-1 and EpsinR.
SMAP2, SMAP1, and GAP1 all exhibited a lack of prefer-
ence for both Arf1 and Arf6 in our in vitro GAP assay. This
suggests that the ArfGAP domain itself does not necessarily
direct the substrate specificity of an ArfGAP toward a par-
ticular isoform of Arf. Therefore, to determine which sub-
strate is preferred by SMAP2, we first assessed the subcel-
lular localization of SMAP2. We found that SMAP2 is
localized on the AP-1– and EpsinR-positive subcellular
structures, but not on the AP-3- or COPI-positive intracellu-
lar organelles. Because the combination of AP-1 and EpsinR
indicates a specific adaptor for the clathrin-coat on the early
endosome (Saint-Pol et al., 2004), the observed colocalization
pattern implies that SMAP2 functions in an early endosome-
to-TGN pathway that is known to be regulated by Arf1.
Indeed, we then found that SMAP2 colocalizes with the
TGN38/46 protein and with transferrin molecules on endo-
somes. Furthermore, we could demonstrate that overexpres-
sion of SMAP2 delays the TGN-accumulation of CD25-
TGN38, a cargo protein known to be transported from the
early endosome to the TGN. This is probably due to the
inactivation of Arf1 by SMAP2 and may reflect the impair-
ment of vesicle budding. The observed effects of R56Q and
CBm mutants on the transport need some discussion
though. A GAP-negative R56Q mutation should keep Arf1
as an active state, thereby likely promoting the vesicle bud-
ding. On the other hand, the lack of GAP activity may not
allow vesicles to be uncoated. Thus, the apparent accumu-
lation of TGN38 may represent not the TGN itself but actu-
ally the endosomes located near the TGN. In the case of CBm
mutation, the clathrin molecules may not be recruited to the
membranes, thereby resulting in the significant impairment
of vesicle budding. In any case, the present study indicates
that SMAP2 can function in a retrograde early endosome-
to-TGN pathway. This also substantiates the notion pro-
posed by ourselves as well as others that each ArfGAP
member acts specifically in a distinct route of vesicle trans-
port inside the cell.
Both SMAP2 and SMAP1 harbor a clathrin box and we
showed that both indeed interact with CHC. That both
SMAPs interact with clathrin is feasible because the path-
ways involving SMAP2 (endosome-to-TGN) and SMAP1
(endocytosis from the plasma membrane) are known to
utilize clathrin-coated vesicles. The clathrin box in SMAP2
may mediate the indirect interaction between Arf1 and
clathrin on the early endosome, similar to the case of
SMAP1, as we previously discussed (Tanabe et al., 2005). It
must be noted though that, unlike SMAP1, both the classical
LLGLD and the atypical DLL motifs appear to contribute to
the clathrin-binding in the case of SMAP2. In addition to the
SMAPs, Git1 is another example of an ArfGAP that is in-
volved in clathrin-dependent transport. Ligand-dependent
endocytosis of G protein–coupled receptors is mediated by
Git1 (Claing et al., 2000), and we could detect a canonical
clathrin box in Git1 (aa 607-611, unpublished data). A TGN-
to-endosome pathway also utilizes clathrin-coated vesicles,
but the candidate ArfGAP that may act in this pathway has
not been identified so far. Instead, GGA1 is reported to
function in this process, and this GGA1 binds not only to
clathrin but also to Arf1 (Ghosh and Kornfeld, 2004). There-
fore, the presence of clathrin box may be a common feature
of the ArfGAPs and GGA1 that are involved in clathrin-
dependent vesicle transport.
We could also demonstrate that SMAP2 interacts with
CALM and identified a CALM-interacting domain in the
carboxy-terminal portion of SMAP2. CALM and AP180 are
isoforms and are expressed ubiquitously and specifically in
the brain, respectively (Tebar et al., 1999). In cells that are
deficient for LAP (an AP180-homologue in Drosophila), the
uniformity of clathrin-coated vesicle size is lost (Zhang et al.,
1998; Hao et al., 1999). Thus, CALM/AP180 is considered to
induce clathrin assembly and to shape the vesicles into an
uniform size. Although it is not yet clear whether CALM is
involved in vesicle transport from the endosome, it is pos-
sible that SMAP2, Arf1, clathrin, and CALM together form a
higher order complex at the site of vesicle budding from the
endosome.
Treatment of cells with BFA disperses the AP-1 molecules
that are accumulated on the early endosomes. We did not
see this effect in SMAP2R56Q-transfected cells, although
AP-1 and SMAP2R56Q had different localization. One pos-
sibility is that the mutant displaces the endogenous SMAP2
from membranes, thereby stabilizing the Arf. An alternative
possibility is that the mutant forms a complex with the
endogenous SMAP2 and trap it in a nonfunctional state.
Observations supporting the latter possibility are described
in Supplementary Figure S2. Whichever the mechanisms
might be, the observation strongly favors the notion that
SMAP2 functions as an Arf1GAP on the early endosomes. In
contrast, SMAP1 regulates Arf6-dependent endocytosis
from the plasma membrane. Therefore, a reasonable ques-
tion would be why the homologous SMAP2 and SMAP1
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behave so differently in vivo. We found four domains that
were conserved between SMAP2 and SMAP1. These corre-
spond to a GAP domain, a clathrin-interacting domain, a
domain of unknown function and a CALM-interacting do-
main. These conserved domains probably do not contain the
putative region that is responsible for the different activities
of SMAP2 and SMAP1 in vesicle transport. This putative
disparate region in the SMAP proteins may be responsible
for their different subcellular localizations (SMAP2 on the
early endosome and SMAP1 on the plasma membrane) and
eventually their specificities for different Arf isoforms
(SMAP2 for Arf1 and SMAP1 for Arf6). Thus, these two
SMAP proteins, which appear to act in important and dis-
tinct pathways of vesicle transport, may help to further
dissect the molecular mechanisms involved in these path-
ways.
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